Literature DB >> 4065698

Conjugated bile acids in serum and secretions in response to cholecystokinin/secretin stimulation in children with cystic fibrosis.

T A Robb, G P Davidson, C Kirubakaran.   

Abstract

More than 80% of patients with cystic fibrosis have poor pancreatic function, and have large daily faecal bile acid losses. This has been postulated to lower luminal bile acid concentrations and adversely affect fat absorption. We studied, for the first time, quantitative individual conjugated duodenal bile acid secretion rates into the duodenum during cholecystokinin/secretin infusion in 55 cystic fibrosis patients and six controls, using a quantitative non-absorbable marker technique. We were able to show adequate duodenal total bile acid concentrations and normal secretion rates in these children. The bile acid secretion pattern in cystic fibrosis patients showed a marked increase in bile acid concentration during cholecystokinin/secretin infusion, to levels which were above the critical micellar concentration indicating that the gall bladder is a functional organ in this disease. The subsequent fall in secretion rate was similar to controls. We have documented a significantly raised glycine/taurine bile acid conjugation ration in duodenal juice from cystic fibrosis patients and suggest that the combined effects of lowered ileal pH and increased glycine conjugated proportion of bile acids may cause precipitation of bile acids leading to decreased fat absorption and large faecal bile acid losses. To further investigate bile acid secretion in children with cystic fibrosis, we modified the high performance thin layer chromatography/densitometry method to enable measurement of individual glycine and taurine conjugates in serum. In comparing cystic fibrosis patients and controls, we were able to determine a group of 18 (36%) with bile acid evidence of liver damage who also showed reduced bile acid secretion into the duodenum. We were unable to study changes in serum bile acids during cholecystokinin/secretin infusion because of the high level of bile acid contamination in Boots Secretin. Some patients showed raised fasting serum bile acid concentrations more than two years before changes in conventional liver function tests or clinically evident liver disease. We have shown fasting serum bile acids to be a sensitive measure of liver dysfunction in cystic fibrosis and postulate that raised proportions of glycine conjugated bile acids may be responsible for the high incidence of liver disease in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4065698      PMCID: PMC1432905          DOI: 10.1136/gut.26.11.1246

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  35 in total

1.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

2.  Increased ratio of glycine- to taurine-conjugated bile salts in patients with ileal disorders.

Authors:  J T Garbutt; K W Heaton; L Lack; M P Tyor
Journal:  Gastroenterology       Date:  1969-04       Impact factor: 22.682

3.  Clinical value of bile salt tests in anicteric liver disease.

Authors:  J G Douglas; G J Beckett; I A Nimmo; N D Finlayson; I W Percy-Robb
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

4.  Lithocholate cholestasis--sulfated glycolithocholate-induced intrahepatic cholestasis in rats.

Authors:  I M Yousef; B Tuchweber; R J Vonk; D Massé; M Audet; C C Roy
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

5.  Abnormal biliary lipid composition in cystic fibrosis. Effect of pancreatic enzymes.

Authors:  C C Roy; A M Weber; C L Morin; J C Combes; D Nusslé; A Mégevand; R Lasalle
Journal:  N Engl J Med       Date:  1977-12-15       Impact factor: 91.245

Review 6.  Relationship between bile acid malabsorption and pancreatic insufficiency in cystic fibrosis.

Authors:  A M Weber; C C Roy; L Chartrand; G Lepage; O L Dufour; C L Morin; R Lasalle
Journal:  Gut       Date:  1976-04       Impact factor: 23.059

7.  Immunoassay of serum conjugates of cholic acid in cystic fibrosis.

Authors:  G P Davidson; M Corey; F Morad-Hassel; J M Sondheimer; D Crozier; G G Forstner
Journal:  J Clin Pathol       Date:  1980-04       Impact factor: 3.411

8.  Bile lipid alterations in taurine-depleted monkeys.

Authors:  Z F Stephan; M J Armstrong; K C Hayes
Journal:  Am J Clin Nutr       Date:  1981-02       Impact factor: 7.045

9.  Excretion of bile acids in healthy children and children with cystic fibrosis.

Authors:  A Eklund; A Norman; B Strandvik
Journal:  Scand J Clin Lab Invest       Date:  1980       Impact factor: 1.713

10.  Fasting serum bile acids in liver disease. A comparison with histological features.

Authors:  R Alm; J Carlson; S Eriksson
Journal:  Scand J Gastroenterol       Date:  1982-03       Impact factor: 2.423

View more
  8 in total

1.  Liver and biliary problems in cystic fibrosis.

Authors:  M S Tanner
Journal:  J R Soc Med       Date:  1992       Impact factor: 5.344

2.  Bile acid secretion in cystic fibrosis.

Authors:  G P Davidson; T A Robb
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

3.  Failure of taurine to improve fat absorption in cystic fibrosis.

Authors:  G N Thompson
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

Review 4.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

5.  The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease.

Authors:  Peter J Lewindon; Tamara N Pereira; Anita C Hoskins; Kim R Bridle; Richard M Williamson; Ross W Shepherd; Grant A Ramm
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

6.  Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine.

Authors:  V T Tsang; A Johnston; F Heritier; N Leaver; M E Hodson; M Yacoub
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Mechanisms of lipid malabsorption in Cystic Fibrosis: the impact of essential fatty acids deficiency.

Authors:  N Peretti; V Marcil; E Drouin; E Levy
Journal:  Nutr Metab (Lond)       Date:  2005-05-03       Impact factor: 4.169

8.  Signals for Hepatic Figrogenesis in Pediatric Cholestatic Liver Disease: Review and Hypothesis.

Authors:  Grant A Ramm; Anita C Hoskins; Sonia A Greco; Tamara N Pereira; Peter J Lewindon
Journal:  Comp Hepatol       Date:  2004-01-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.